Beshoy Yanny, MD
Transplant Hepatology · Los Angeles, CANPI 1417221243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,821 of the $50,291 with a category attached, or 83.2%. Madrigal Pharmaceuticals accounts for 80.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $35,129, more than ten times the $470 reported in 2019.
Across 73 payments — averaging $688.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$41K
- Ipsen Biopharmaceuticals, Inc$7K
- Gilead$1K
- Eton Pharmaceuticals, Inc.$1K
- Intercept Pharmaceuticals, Inc.$178
- Novo Nordisk$74
- plus $189 from 4 others
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$41,82183%
- Travel & lodging$2,9956%
- Food & beverage$4,4769%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 41 | $40,607 |
| Ipsen Biopharmaceuticals, Inc | 7 | $7,171 |
| Gilead | 15 | $1,073 |
| Eton Pharmaceuticals, Inc. | 1 | $1,000 |
| Intercept Pharmaceuticals, Inc. | 4 | $178 |
| Novo Nordisk | 1 | $74 |
| Echosens North America, Inc. | 1 | $70 |
| AbbVie | 1 | $59 |
| VBI Vaccine (delaware) Inc. | 1 | $36 |
| Lilly USA, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$39,458
- IQIRVO$7,061
- GALZIN$1,000
- CARGLUMIC ACID$1,000
- BETAINE ANHYDROUS$1,000
- NITISINONE$1,000
- RESMETIROM$412
- OCALIVA$128
How this compares
$50,291 in reported general payments places this provider in the 85th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 42 | $168,021 |
| VemlidyTenofovir Alafenamide | 107 | $156,787 |
| Ursodiol | 69 | $13,889 |
| Entecavir | 57 | $9,696 |
| Mycophenolate Mofetil | 17 | $963 |
| Bumetanide | 12 | $617 |
| Spironolactone | 21 | $303 |
| Ciprofloxacin Hcl | 13 | $118 |
| Furosemide | 20 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $1,073 | $156,787107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 39 transplant hepatology providers in California.
Other transplant hepatology in Los Angeles
- Julio GutierrezLos Angeles$895K
- Pei Lim LeeLos Angeles$79K
- Kali ZhouLos Angeles$50K
- Jasleen SinghLos Angeles$46K
- Norah TerraultLos Angeles$13K
- Jeffrey KahnLos Angeles$9K
- Brian KimLos Angeles$7K
- Tse Ling FongLos Angeles$6K
- Liyun YuanLos Angeles$4K
- Cynthia CherfaneLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.